This page shows the latest Steglatro news and features for those working in and with pharma, biotech and healthcare.
NICE has cleared MSD’s type 2 diabetes treatment Steglatro for routine NHS use in combination with metformin, or as a monotherapy for those who are intolerant to the anti-diabetic ... MSD is hoping Steglatro can take market share from other more
Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest oral treatment options for diabetes, but SGLT-2 inhibitor Steglatro will be a late ... Steglatro has now been launched in the US and an EMA
Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2 ... Steglatro and Steglujan are
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Steglatro launched as a new SGLT2 in early 2019 and was quickly bolstered by two NICE TAs. ... Armed with positive NICE guidance, MSD did a great job of getting Steglatro on formulary.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...